Medtronic saw $9 billion in global revenue, a 6.6% year over year increase, in the second quarter of fiscal year 2026, according to financial results posted Nov. 18.
Five things to know:
1. Medtronic’s cardiology segment saw double-digit growth (10.8% year over year) with $3.3 billion. Within that branch, cardiac rhythm and heart failure saw 15.7% growth, followed by structural heart and coronary sales.
2. Neuroscience sales were $2.5 billion, a 4.5% increase year over year. Cranial and spinal technologies saw 5.2% year over year growth with $1.3 billion. Specialty therapies and neuromodulation saw year-over-year growth of 0.9% and 8.3%, respectively.
3. Medical Surgical business was $2.2 billion, a 2.1% increase year over year, and cardiovascular sales were $3.6 billion, a 10.8% jump. Diabetes revenue was $757 million, a 10.3& year over year increase.
4. “We delivered a strong second quarter, with both revenue and EPS beating expectations. Overall, procedure volumes and our end markets are robust, and we’re executing well across the business,” chair and CEO Geoff Martha, said in the release. “Looking ahead, we are positioned for even greater acceleration of revenue growth in the back half of the year and beyond, driven by several enterprise growth drivers, including our PFA franchise for Afib, Symplicity procedure for hypertension, Hugo™ robotic-assisted surgery system, and Altaviva therapy for urge urinary incontinence.”
5. Medtronic raised its fiscal year 2026 guidance and expects 5.5% full-year growth.
